# The Safety and Effectiveness of Ganciclovir Plus Interferon Beta in Preventing the Return of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS

> **NCT00002299** · NA · COMPLETED · sponsor: **Hoffmann-La Roche**

## Conditions studied

- Cytomegalovirus Retinitis
- HIV Infections

## Interventions

- **DRUG:** Interferon beta-1b
- **DRUG:** Ganciclovir

## Key facts

- **NCT ID:** NCT00002299
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2005-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002299

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002299, "The Safety and Effectiveness of Ganciclovir Plus Interferon Beta in Preventing the Return of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00002299. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*